Hospital
Rumford Hospital
Rumford Hospital was paid $2.35M by Medicaid between Jan 2018 and Dec 2024, across 219 billing codes. Its largest line is 99285, emergency room visit (most serious) — 16% of everything it billed.
33Billing provider infoRUMFORD HOSPITAL
RUMFORD, ME 04276
RUMFORD, ME 04276
33aNPI1205991122assigned 12/22/2006
33bProvider typeCritical Access Hospital
28Total paid$2.35M
24GClaims421,104
24DCodes billed219
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Maine
Rank by total paid#7 of 14
Median peer was paid$1.76M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,534 | $413K | |
| 2019 | 63,785 | $381K | |
| 2020 | 47,975 | $229K | |
| 2021 | 60,002 | $285K | |
| 2022 | 70,978 | $344K | |
| 2023 | 63,512 | $352K | |
| 2024incomplete | 52,318 | $342K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 11,547 | 7,101 | $371K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 25,599 | 15,820 | $276K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.0% | 28,642 | 17,951 | $189K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 2,746 | 2,535 | $160K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.3% | 3,927 | 2,772 | $100K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 1,905 | 1,722 | $98K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.7% | 4,263 | 3,206 | $88K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.2% | 6,216 | 4,612 | $75K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 6,606 | 5,449 | $70K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 9,074 | 7,569 | $65K |
| G0378 | Hospital observation service, per hour | 2.7% | 1,488 | 614 | $63K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 10,570 | 4,242 | $50K |
207 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.9% | 5,328 | $45K |
| 80053 | Comprehensive metabolic panel | 1.8% | 23,268 | $43K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.6% | 5,805 | $37K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.5% | 367 | $35K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 3,834 | $33K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 10,368 | $32K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.3% | 6,451 | $31K |
| 99215 | Doctor's office visit, returning patient (complex) | 1.2% | 2,431 | $28K |
| 96376 | 1.2% | 2,133 | $28K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 961 | $23K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 344 | $21K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 418 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,612 | $15K |
| 73630 | <1% | 1,804 | $15K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,521 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,479 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,034 | $14K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,353 | $13K |
| 36415 | Collection of venous blood by venipuncture | <1% | 30,365 | $12K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,368 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,446 | $11K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,587 | $11K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 255 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,277 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,753 | $10K |
| 97162 | <1% | 785 | $9K | |
| 97161 | <1% | 1,147 | $8K | |
| 11721 | <1% | 1,289 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,308 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 107 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 422 | $7K |
| 71250 | <1% | 71 | $7K | |
| J3490 | Unclassified drugs | <1% | 368 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 134 | $6K |
| 73030 | <1% | 353 | $6K | |
| 73562 | <1% | 378 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,142 | $5K |
| 85610 | <1% | 5,325 | $5K | |
| 84484 | <1% | 4,678 | $5K | |
| 96367 | <1% | 455 | $4K | |
| 73610 | <1% | 729 | $4K | |
| 83880 | <1% | 1,333 | $4K | |
| 73130 | <1% | 371 | $4K | |
| 72100 | <1% | 258 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,738 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 404 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,426 | $3K |
| 73502 | <1% | 206 | $3K | |
| 82728 | <1% | 1,575 | $3K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 13 | $3K |
| 80069 | <1% | 775 | $3K | |
| 85027 | <1% | 4,591 | $3K | |
| 87088 | <1% | 3,948 | $2K | |
| 81001 | <1% | 6,418 | $2K | |
| 82043 | <1% | 758 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,320 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 177 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 533 | $2K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 7,666 | $2K |
| 83735 | <1% | 3,540 | $2K | |
| 80061 | Lipid panel | <1% | 6,494 | $2K |
| 82607 | <1% | 1,145 | $2K | |
| 86140 | <1% | 2,530 | $2K | |
| 84439 | <1% | 1,279 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 267 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 352 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,186 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 361 | $1K |
| 83550 | <1% | 1,385 | $1K | |
| 94760 | <1% | 286 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,010 | $1K |
| 83605 | <1% | 2,439 | $1K | |
| 82805 | <1% | 788 | $1K | |
| 73110 | <1% | 98 | $1K | |
| 80051 | <1% | 2,756 | $1K | |
| 87040 | <1% | 1,510 | $1K | |
| 87186 | <1% | 1,783 | $1K | |
| 83540 | <1% | 1,505 | $1K | |
| 99217 | <1% | 382 | $1K | |
| 83690 | <1% | 4,395 | $1K | |
| 94644 | <1% | 92 | $1K | |
| 85651 | <1% | 1,998 | $1K | |
| 97116 | <1% | 422 | $991.07 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,916 | $878.85 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,752 | $840.87 |
| 36410 | <1% | 23 | $837.84 | |
| 82565 | <1% | 3,155 | $822.47 | |
| 81003 | <1% | 3,556 | $770.84 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,145 | $698.50 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,280 | $694.57 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 107 | $691.39 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,081 | $637.99 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 42 | $631.71 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 46 | $622.98 |
| 86803 | <1% | 702 | $622.34 | |
| 99219 | <1% | 111 | $621.33 | |
| 84520 | <1% | 2,980 | $593.97 | |
| 84460 | <1% | 935 | $587.67 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 34 | $586.08 |
| 90715 | <1% | 98 | $553.15 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 13 | $532.71 |
| 82746 | <1% | 412 | $508.67 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 794 | $467.57 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 17 | $459.56 |
| 87077 | <1% | 863 | $405.78 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,259 | $393.01 |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,720 | $386.53 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 18 | $366.72 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 272 | $341.77 |
| 80076 | <1% | 55 | $313.91 | |
| 84450 | <1% | 901 | $270.84 | |
| 85380 | <1% | 604 | $250.25 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 437 | $248.93 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 128 | $247.52 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 88 | $223.72 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 853 | $213.93 |
| 97166 | <1% | 30 | $201.79 | |
| 81025 | <1% | 4,154 | $159.62 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,691 | $156.81 |
| 86352 | <1% | 165 | $155.61 | |
| 82248 | <1% | 820 | $146.84 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 32 | $141.74 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 369 | $141.56 |
| 82570 | <1% | 56 | $139.07 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 437 | $137.73 |
| 70498 | <1% | 12 | $130.92 | |
| 74019 | <1% | 16 | $126.93 | |
| 86618 | <1% | 13 | $124.83 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 247 | $114.12 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 172 | $112.72 |
| 87081 | <1% | 1,265 | $108.58 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 38 | $102.98 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,964 | $102.72 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,589 | $100.78 |
| 85730 | <1% | 362 | $99.28 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 338 | $97.30 |
| 87205 | <1% | 371 | $90.92 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 323 | $88.81 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 30 | $87.26 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 949 | $84.14 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,589 | $82.48 |
| 87070 | <1% | 204 | $75.24 | |
| 82947 | <1% | 2,209 | $74.49 | |
| 84100 | <1% | 260 | $70.05 | |
| 59025 | Fetal non-stress test | <1% | 149 | $69.59 |
| 80306 | <1% | 345 | $69.55 | |
| 85018 | <1% | 180 | $68.11 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 111 | $65.65 |
| 83970 | <1% | 16 | $64.87 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 20 | $63.11 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 25 | $58.82 |
| 87147 | <1% | 584 | $55.79 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 51 | $48.42 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 20 | $43.58 |
| 82040 | <1% | 289 | $43.36 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 29 | $43.01 |
| 81002 | <1% | 934 | $41.77 | |
| 86703 | <1% | 173 | $40.24 | |
| 99218 | <1% | 13 | $38.96 | |
| 76830 | Ultrasound, transvaginal | <1% | 30 | $37.83 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 15 | $36.66 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 116 | $35.34 |
| 83516 | <1% | 15 | $30.80 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,384 | $29.58 |
| 97035 | <1% | 78 | $26.00 | |
| 88142 | <1% | 402 | $25.14 | |
| 87340 | <1% | 108 | $23.25 | |
| 84075 | <1% | 272 | $22.86 | |
| 87581 | <1% | 369 | $21.61 | |
| 71271 | <1% | 25 | $21.39 | |
| 82247 | <1% | 277 | $18.13 | |
| 84156 | <1% | 28 | $16.41 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 264 | $15.66 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 21 | $15.62 |
| Q3014 | Telehealth originating site facility fee | <1% | 42 | $14.93 |
| 84702 | <1% | 126 | $13.75 | |
| 82272 | <1% | 13 | $13.18 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 17 | $12.76 |
| 86850 | <1% | 26 | $12.12 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 160 | $9.86 |
| 86900 | <1% | 51 | $6.75 | |
| 86901 | <1% | 51 | $6.67 | |
| 86038 | <1% | 29 | $5.98 | |
| 84132 | <1% | 14 | $5.39 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 104 | $4.05 |
| 96368 | <1% | 15 | $1.75 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 13 | $1.18 |
| 82010 | <1% | 15 | $0.51 | |
| 87210 | <1% | 15 | $0.48 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 115 | $0.01 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 75 | $0.00 |
| 0002A | 0% | 60 | $0.00 | |
| 87660 | 0% | 93 | $0.00 | |
| 91300 | 0% | 133 | $0.00 | |
| 0071A | 0% | 39 | $0.00 | |
| 81000 | 0% | 55 | $0.00 | |
| 87480 | 0% | 93 | $0.00 | |
| 0012A | 0% | 457 | $0.00 | |
| 0011A | 0% | 330 | $0.00 | |
| 91301 | 0% | 795 | $0.00 | |
| 87510 | 0% | 93 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 54 | $0.00 |
| 91307 | 0% | 75 | $0.00 | |
| 0001A | 0% | 72 | $0.00 | |
| 84703 | 0% | 28 | $0.00 | |
| 82150 | 0% | 16 | $0.00 | |
| 0072A | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORIN, SUE (REGIONAL MANAGER PHYSICIAN PRACTICE)
| Provider | Location | Paid |
|---|---|---|
| Bridgton Hospital | Bridgton, ME | $2.52M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.